BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/25/2025 12:09:40 PM | Browse: 4 | Download: 23
 |
Received |
|
2025-04-08 11:07 |
|
Peer-Review Started |
|
2025-04-10 00:12 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-04-25 09:31 |
|
Revised |
|
2025-04-29 22:38 |
|
Second Decision |
|
2025-06-13 02:50 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-06-13 08:32 |
|
Articles in Press |
|
2025-06-13 08:32 |
|
Publication Fee Transferred |
|
2025-05-05 20:06 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-07-16 01:15 |
|
Publish the Manuscript Online |
|
2025-07-25 12:09 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Three-year outcomes of tumor necrosis factor alpha inhibitor therapy in rheumatoid arthritis patients with elevated liver enzymes
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shivangini Duggal, Lakshmi Kattamuri and Shrilekha Sairam |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Shivangini Duggal, MD, Department of Internal Medicine, Texas Tech University Health Sciences Center, 4801 Alberta Ave, El Paso, TX 79905, United States. sduggal@ttuhsc.edu |
| Key Words |
Elevated liver enzymes; Rheumatoid arthritis; Etanercept; Adalimumab; Fibrosis-4 scores |
| Core Tip |
Rheumatoid arthritis (RA) patients often present with elevated liver enzymes, complicating the safe administration of immunosuppressive therapies. This retrospective study evaluated the hepatic safety of tumor necrosis factor inhibitors (TNFi)—etanercept and adalimumab—in RA patients with persistently elevated liver enzymes. Over a 3-year follow-up, TNFi therapy led to statistically significant improvements in aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and fibrosis-4 scores, without hepatic decompensation or changes in Child-Pugh class. These findings suggest that TNFi therapy may be hepatologically safe and potentially beneficial in liver enzyme normalization among this high-risk population. |
| Publish Date |
2025-07-25 12:09 |
| Citation |
<p>Duggal S, Kattamuri L, Sairam S. Three-year outcomes of tumor necrosis factor alpha inhibitor therapy in rheumatoid arthritis patients with elevated liver enzymes. <i>World J Hepatol</i> 2025; 17(7): 108051</p> |
| URL |
https://www.wjgnet.com/1948-5182/full/v17/i7/108051.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v17.i7.108051 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
